Researchers identified a novel cerebrospinal fluid (CSF) protein ratio, YWHAG:NPTX2, as a robust biomarker for predicting cognitive resilience and disease progression in patients with Alzheimer's disease, showing significant predictive capacity for future cognitive outcomes. This biomarker highlights synapse dysfunction as a potential therapeutic target and may have implications for clinical trial patient selection and therapeutic efficacy evaluation.

Source: Nature Medicine